Dr Reddy’s Zytorvi approval is the latest India-specific cancer decision: the country’s drug regulator has approved toripalimab, sold as Zytorvi, with cisplatin and paclitaxel as a first-line treatment for eligible adults with advanced, recurrent or metastatic esophageal squamous cell carcinoma, according to the company’s disclosure reported on 21 October 2026. Dr. Reddy’s Laboratories holds the rights to the drug in India under a licence from Junshi Biosciences. The final Phase 3 JUPITER-06 results, which are company-reported, show median overall survival of 17.7 months with the combination versus 12.9 months with chemotherapy alone. This is a prescription cancer medicine, and the report is general information and not medical advice.
Dr Reddy’s Zytorvi approval: key takeaways
- India’s regulator has approved Zytorvi (toripalimab) plus cisplatin and paclitaxel as first-line treatment for eligible adults with advanced, recurrent or metastatic esophageal squamous cell carcinoma.
- It is reported to be used without PD-L1 testing for patient selection, and it is Zytorvi’s second Indian indication after nasopharyngeal carcinoma.
- In JUPITER-06, median overall survival was 17.7 months with toripalimab plus chemotherapy versus 12.9 months with chemotherapy alone (hazard ratio 0.72).
- The 42% figure seen in some reports refers to progression-free survival, not overall survival.
- The trial was run in China, and the approval date, price and launch timing have not been disclosed.
What the Dr Reddy’s Zytorvi approval covers
According to reports of Dr. Reddy’s disclosure, the Central Drugs Standard Control Organisation, headed by the Drugs Controller General of India, approved Zytorvi for first-line use with cisplatin and paclitaxel in adults with unresectable, advanced, recurrent or metastatic esophageal squamous cell carcinoma, often shortened to ESCC. The reports say patients do not need PD-L1 testing to be selected. This is the drug’s second indication in India, after nasopharyngeal carcinoma. The reports we reviewed did not give the approval date, and we could not see the label text, so we rely on the reported description. General regulator information is on the Central Drugs Standard Control Organisation website.
JUPITER-06 results behind the Dr Reddy’s Zytorvi approval
JUPITER-06 randomised 514 adults with previously untreated advanced ESCC to toripalimab or placebo, each combined with paclitaxel and cisplatin, across 72 centres in China. In the final overall survival analysis presented at ESMO Asia 2025, Junshi Biosciences reported median overall survival of 17.7 months with toripalimab and 12.9 months with placebo, a hazard ratio of 0.72, which the company describes as a 28% reduction in the risk of death (p=0.002). Survival at one, two and three years was 64.4%, 39.1% and 29.7% with toripalimab versus 54.5%, 27.1% and 19.9% with placebo. The company’s release is the source for these figures, which come from its own Junshi Biosciences’ release on the final analysis.
Where the 42% figure comes from
Some reports on the Indian approval mention a 42% reduction in the risk of disease progression or death. That matches the progression-free survival result in the primary JUPITER-06 publication in Cancer Cell, where the hazard ratio was 0.58. It does not describe overall survival, for which the final hazard ratio was 0.72, or a 28% reduction in the risk of death. The two numbers answer different questions, one about delaying progression and the other about living longer, and should not be used interchangeably. By our arithmetic, the survival gain is 4.8 months at the median.
Does PD-L1 matter?
In the original analysis, the progression-free survival benefit appeared across PD-L1 groups, with hazard ratios of 0.58 for a combined positive score of at least 1 and 0.66 for below 1. The final analysis found no significant PD-L1 interaction for overall survival. That is consistent with the reported approval not requiring PD-L1 testing, though it is the regulator’s label, not the trial subgroups, that governs how the drug is used in India.
Safety findings for the Dr Reddy’s Zytorvi approval
The Cancer Cell publication reported grade 3 or higher treatment-emergent adverse events in 73.2% of patients on toripalimab and 70.0% on placebo, with fatal events at 8.2% in both arms. Grade 3 or higher neutropenia was more frequent with toripalimab, at 42.4% versus 33.1%, and immune-related adverse events were 37.0% versus 26.5%, with grade 3 or higher at 7% versus 1.6%. Junshi’s later release says no new safety signals emerged in long-term follow-up. Immune-related side effects are a known feature of this drug class and need monitoring by the treating team.
Dr Reddy’s Zytorvi approval: who was studied, and why it matters
All patients in JUPITER-06 were Chinese and had squamous histology, so the results do not by themselves confirm the same effect in other populations or in adenocarcinoma of the oesophagus. Squamous cell carcinoma is the predominant type in many Asian countries, which makes the data relevant to India, but this is our reading, and the approval does not mean Indian patients were in the trial. The trial’s trial registry entry (NCT03829969) lists the study design.
Dr Reddy’s Zytorvi approval and the licensing deal
Dr. Reddy’s licensed toripalimab from Junshi Biosciences in 2023, with exclusive rights to develop and market it in 21 countries including India, according to the reports. The same reports say toripalimab is approved by the U.S. FDA, the European Medicines Agency and the UK regulator, which we have not independently confirmed for this indication. In India, the drug was first approved for nasopharyngeal carcinoma, and Dr. Reddy’s launched it for that use in November 2024.
What the Dr Reddy’s Zytorvi approval leaves undisclosed
- The date of the regulator’s approval and the exact label wording.
- Price, launch date and patient-access arrangements.
- Any India-specific trial or post-approval study.
- Whether the company will publish additional Indian data.
Risks and caveats on Dr Reddy’s Zytorvi approval
- Trial results are company-reported or from a trial in Chinese patients, and may not predict outcomes for every patient.
- Median survival differences describe groups, not individuals.
- We have not seen the label, and reports differ in detail.
- This is news reporting, not medical advice, and treatment decisions belong with an oncologist.
In our assessment, the Dr Reddy’s Zytorvi approval widens first-line options for a hard-to-treat cancer in India, and its practical impact will depend on price, access and how clinicians use the PD-L1-independent label. See also Indian Pharmaceutical Market Grows 17.1%: Strong Surge. More in our pharmaceutical coverage.
What to watch next on Dr Reddy’s Zytorvi approval
- Launch timing and pricing in India.
- The published label and prescribing information.
- Real-world Indian outcomes as use begins.
Frequently asked questions
What did India approve?
Zytorvi (toripalimab) with cisplatin and paclitaxel as first-line treatment for eligible adults with advanced, recurrent or metastatic esophageal squamous cell carcinoma, per the company disclosure as reported.
How much longer did patients live in JUPITER-06?
Median overall survival was 17.7 months with toripalimab plus chemotherapy versus 12.9 months with chemotherapy alone.
Is Zytorvi a cure?
No. It is a treatment shown to extend survival on average in a clinical trial, and outcomes vary by patient.
How we reported this: we relied on reports of the company’s disclosure of 21 October 2026, the JUPITER-06 publication, the trial registry and a company release on the final analysis. Our arithmetic and general background are labelled. Last updated: 21 October 2026. This article is news reporting and not medical advice.